Benralizumab for adolescent patients with severe, eosinophilic asthma: Safety and efficacy after 3 years of treatment
William W. Busse, Eugene R. Bleecker, J. Mark FitzGerald, Gary T. Ferguson, Peter Barker, Laura Brooks, Richard F. Olsson, Ubaldo J. Martin, Mitchell Goldman
Topics & Concepts
BenralizumabPlaceboMedicineExacerbationAdverse effectAsthma exacerbationsAsthmaDiscontinuationInternal medicineEosinophilMepolizumabPathologyAlternative medicineAsthma and respiratory diseasesChronic Obstructive Pulmonary Disease (COPD) ResearchDelphi Technique in Research